| John D Despain, MD | |
|
5721 Osage Beach Pkwy Ste 100, Osage Beach, MO 65065-3030 | |
| (573) 302-4696 | |
| (573) 302-4698 |
| Full Name | John D Despain |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 40 Years |
| Location | 5721 Osage Beach Pkwy Ste 100, Osage Beach, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932196433 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ND0900X | Dermatology - Dermatopathology | R8E64 (Missouri) | Secondary |
| 207N00000X | Dermatology | R8E64 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lake Regional Health System | Osage beach, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Forefront Dermatology | 3779471701 | 474 |
News Archive
Living Cell Technologies Limited, a company pioneering the development of a cell implant to treat diabetes, has obtained approval to commence a Phase II DIABECELL clinical trial in Buenos Aires, Argentina, DIABECELL's third jurisdiction to date which has approved human trials. Up to eight adult patients with Type 1 diabetes, including those with unstable diabetes and severe hypoglycaemia, will each receive two implants of DIABECELL, three months apart with a dose seeking component. The trial is expected to begin in the second half of this year.
In a new study presented today at the 2013 Annual Meeting of the American Academy of Orthopaedic Surgeons, researchers reviewed existing literature on smoking and the healing of fractures involving long bones (bones that are longer than they are wide).
People who had cancer before receiving an organ transplant were more likely to die of any cause, die of cancer or develop a new cancer than organ recipients who did not previously have cancer, a new paper has found. However, the increased risk is less than that reported in some previous studies.
Changes in the format of a federal database for mandatory reporting of major and minor complications for medical devices, including cochlear implants, could make it a valuable resource, according to an article in the March issue of Archives of Otolaryngology – Head & Neck Surgery.
Health innovation. Things are looking good in terms of the number of participants at the 2017 WHINN - Week and Health and Innovation knowledge festival.
› Verified 5 days ago
| Entity Name | Jefferson City Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336189398 PECOS PAC ID: 1850371089 Enrollment ID: O20040908000924 |
News Archive
Living Cell Technologies Limited, a company pioneering the development of a cell implant to treat diabetes, has obtained approval to commence a Phase II DIABECELL clinical trial in Buenos Aires, Argentina, DIABECELL's third jurisdiction to date which has approved human trials. Up to eight adult patients with Type 1 diabetes, including those with unstable diabetes and severe hypoglycaemia, will each receive two implants of DIABECELL, three months apart with a dose seeking component. The trial is expected to begin in the second half of this year.
In a new study presented today at the 2013 Annual Meeting of the American Academy of Orthopaedic Surgeons, researchers reviewed existing literature on smoking and the healing of fractures involving long bones (bones that are longer than they are wide).
People who had cancer before receiving an organ transplant were more likely to die of any cause, die of cancer or develop a new cancer than organ recipients who did not previously have cancer, a new paper has found. However, the increased risk is less than that reported in some previous studies.
Changes in the format of a federal database for mandatory reporting of major and minor complications for medical devices, including cochlear implants, could make it a valuable resource, according to an article in the March issue of Archives of Otolaryngology – Head & Neck Surgery.
Health innovation. Things are looking good in terms of the number of participants at the 2017 WHINN - Week and Health and Innovation knowledge festival.
› Verified 5 days ago
| Entity Name | Boyce & Bynum Pathology Professional Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689634818 PECOS PAC ID: 0042384976 Enrollment ID: O20080811000335 |
News Archive
Living Cell Technologies Limited, a company pioneering the development of a cell implant to treat diabetes, has obtained approval to commence a Phase II DIABECELL clinical trial in Buenos Aires, Argentina, DIABECELL's third jurisdiction to date which has approved human trials. Up to eight adult patients with Type 1 diabetes, including those with unstable diabetes and severe hypoglycaemia, will each receive two implants of DIABECELL, three months apart with a dose seeking component. The trial is expected to begin in the second half of this year.
In a new study presented today at the 2013 Annual Meeting of the American Academy of Orthopaedic Surgeons, researchers reviewed existing literature on smoking and the healing of fractures involving long bones (bones that are longer than they are wide).
People who had cancer before receiving an organ transplant were more likely to die of any cause, die of cancer or develop a new cancer than organ recipients who did not previously have cancer, a new paper has found. However, the increased risk is less than that reported in some previous studies.
Changes in the format of a federal database for mandatory reporting of major and minor complications for medical devices, including cochlear implants, could make it a valuable resource, according to an article in the March issue of Archives of Otolaryngology – Head & Neck Surgery.
Health innovation. Things are looking good in terms of the number of participants at the 2017 WHINN - Week and Health and Innovation knowledge festival.
› Verified 5 days ago
| Entity Name | Forefront Dermatology Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891179040 PECOS PAC ID: 3779471701 Enrollment ID: O20150922001275 |
News Archive
Living Cell Technologies Limited, a company pioneering the development of a cell implant to treat diabetes, has obtained approval to commence a Phase II DIABECELL clinical trial in Buenos Aires, Argentina, DIABECELL's third jurisdiction to date which has approved human trials. Up to eight adult patients with Type 1 diabetes, including those with unstable diabetes and severe hypoglycaemia, will each receive two implants of DIABECELL, three months apart with a dose seeking component. The trial is expected to begin in the second half of this year.
In a new study presented today at the 2013 Annual Meeting of the American Academy of Orthopaedic Surgeons, researchers reviewed existing literature on smoking and the healing of fractures involving long bones (bones that are longer than they are wide).
People who had cancer before receiving an organ transplant were more likely to die of any cause, die of cancer or develop a new cancer than organ recipients who did not previously have cancer, a new paper has found. However, the increased risk is less than that reported in some previous studies.
Changes in the format of a federal database for mandatory reporting of major and minor complications for medical devices, including cochlear implants, could make it a valuable resource, according to an article in the March issue of Archives of Otolaryngology – Head & Neck Surgery.
Health innovation. Things are looking good in terms of the number of participants at the 2017 WHINN - Week and Health and Innovation knowledge festival.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John D Despain, MD 801 York St, Manitowoc, WI 54220-4630 Ph: (920) 663-9008 | John D Despain, MD 5721 Osage Beach Pkwy Ste 100, Osage Beach, MO 65065-3030 Ph: (573) 302-4696 |
News Archive
Living Cell Technologies Limited, a company pioneering the development of a cell implant to treat diabetes, has obtained approval to commence a Phase II DIABECELL clinical trial in Buenos Aires, Argentina, DIABECELL's third jurisdiction to date which has approved human trials. Up to eight adult patients with Type 1 diabetes, including those with unstable diabetes and severe hypoglycaemia, will each receive two implants of DIABECELL, three months apart with a dose seeking component. The trial is expected to begin in the second half of this year.
In a new study presented today at the 2013 Annual Meeting of the American Academy of Orthopaedic Surgeons, researchers reviewed existing literature on smoking and the healing of fractures involving long bones (bones that are longer than they are wide).
People who had cancer before receiving an organ transplant were more likely to die of any cause, die of cancer or develop a new cancer than organ recipients who did not previously have cancer, a new paper has found. However, the increased risk is less than that reported in some previous studies.
Changes in the format of a federal database for mandatory reporting of major and minor complications for medical devices, including cochlear implants, could make it a valuable resource, according to an article in the March issue of Archives of Otolaryngology – Head & Neck Surgery.
Health innovation. Things are looking good in terms of the number of participants at the 2017 WHINN - Week and Health and Innovation knowledge festival.
› Verified 5 days ago
Karen L Eshraghi, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5721 Osage Beach Pkwy Ste 100, Osage Beach, MO 65065 Phone: 573-302-4696 Fax: 573-302-4698 |